Halozyme Therapeutics, Inc. (HALO) Tops Q3 EPS by 9c, Sales Beat Expectations
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q3 EPS of $0.05, $0.09 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $22.9 million versus the consensus estimate of $19.25 million.